Sugi Predict

Sugi Predict / Compounds / SCHEMBL2006750

SCHEMBL2006750

SCHEMBL2006750

O=C(O)CCc1cn(Cc2ccccc2)c2ccccc12

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PLA2G4A P47712 1/20 0.68
▸ POLB P06746 1/20 0.68
▸ HTR6 P50406 1/20 0.62
▸ LMNA P02545 2/20 0.61
▸ ALDH1A1 P00352 1/20 0.61
▸ PLK1 P53350 2/20 0.57
▸ HDAC6 Q9UBN7 2/20 0.56
▸ HDAC10 Q969S8 1/20 0.56
▸ HDAC1 Q13547 1/20 0.56
▸ HDAC8 Q9BY41 1/20 0.56
▸ CHRNB2 P17787 1/20 0.56
▸ CHRNA7 P36544 1/20 0.56
▸ CHRNA4 P43681 1/20 0.56
▸ CYP19A1 P11511 1/20 0.56
▸ PADI4 Q9UM07 1/20 0.55
▸ YES1 P07947 1/20 0.55
▸ KDR P35968 1/20 0.55
▸ JAK3 P52333 1/20 0.55
▸ MEN1 O00255 1/20 0.55
▸ KMT2A Q03164 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5329307 0.92 POLB (0.72) PLA2G4APOLBHTR6LMNAALDH1A1
SCHEMBL4595500 0.89 POLB (0.64) PLA2G4APOLBHTR6LMNAALDH1A1
SCHEMBL9670003 0.85 POLB (0.60) PLA2G4APOLBHTR6HDAC6HDAC10
SCHEMBL2051630 0.85 ALDH1A1 (0.80) POLBHTR6LMNAALDH1A1PLK1
SCHEMBL5641773 0.84 HTR6 (0.62) PLA2G4APOLBHTR6ALDH1A1HDAC6
SCHEMBL9210193 0.84 PLK1 (0.58) PLA2G4APOLBLMNAPLK1PADI4
SCHEMBL15700115 0.83 POLB (0.83) POLBHTR6LMNAALDH1A1HDAC6
SCHEMBL20248189 0.83 HTR6 (0.62) PLA2G4APOLBHTR6HDAC6HDAC10
SCHEMBL20250911 0.83 RXFP1 (0.62) PLA2G4APOLBLMNAALDH1A1HDAC6
SCHEMBL13061259 0.82 PLK1 (0.57) PLA2G4AHTR6PLK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1146905-A1 COX-2 INHIBITORS IN COMBINATION WITH NMDA-BLOCKERS FOR TREATING PAIN Algos Pharmaceutical Corporation (US) 2001-10-24 — — EP claimed
WO-2000029022-A1 COX-2 INHIBITORS IN COMBINATION WITH CENTRALLY ACTING ANALGESICS ALGOS PHARMACEUTICAL CORPORATION (US) 2000-05-25 — — WO claimed
WO-2000029023-A1 COX-2 INHIBITORS IN COMBINATION WITH NMDA-BLOCKERS FOR TREATING PAIN ALGOS PHARMACEUTICAL CORPORATION (US) 2000-05-25 — — WO claimed
US-20260034071-A1 HIGH-PURITY PEG LIPIDS AND USES THEREOF MODERNATX, INC. (US) 2026-02-05 — — US disclosed
US-12383508-B2 High-purity peg lipids and uses thereof MODERNATX, INC. (US) 2025-08-12 — — US disclosed
US-20250152518-A1 PEG LIPIDS AND USES THEREOF MODERNATX, INC. (US) 2025-05-15 — — US disclosed
EP-4509118-A2 HIGH-PURITY PEG LIPIDS AND USES THEREOF ModernaTX, Inc. (US) 2025-02-19 — — EP disclosed
US-12151029-B2 PEG lipids and uses thereof MODERNATX, INC. (US) 2024-11-26 — — US disclosed
US-20240377399-A1 COMPOSITIONS AND METHODS FOR MODULATING HYDROXYLATION OF ACC2 BY PHD3 PRESIDENT AND FELLOWS OF HARVARD COLLEGE 2024-11-14 — — US disclosed
EP-3853305-B1 HIGH-PURITY PEG LIPIDS AND USES THEREOF MODERNATX INC (US) 2024-10-02 — — EP disclosed
US-11905525-B2 Reduction of elimination of immune responses to non-intravenous, e.g., subcutaneously administered therapeutic proteins MODERNATX, INC. (US) 2024-02-20 — — US disclosed
WO-2000029022-A1 COX-2 INHIBITORS IN COMBINATION WITH CENTRALLY ACTING ANALGESICS ALGOS PHARMACEUTICAL CORPORATION (US) 2000-05-25 — — WO disclosed
WO-2000029023-A1 COX-2 INHIBITORS IN COMBINATION WITH NMDA-BLOCKERS FOR TREATING PAIN ALGOS PHARMACEUTICAL CORPORATION (US) 2000-05-25 — — WO disclosed
US-5877199-A ALZHEIMER'S DISEASE; SEDATIVE SANKYO COMPANY, LIMITED (JP) 1999-03-02 — — US disclosed
EP-0804416-A1 HETEROCYCLIC COMPOUNDS, USEFUL AS ALLOSTERIC EFFECTORS AT MUSCARINIC RECEPTORS SANKYO COMPANY LIMITED (JP) 1997-11-05 — — EP disclosed
US-5604253-A ANTIINFLAMMATORY AGENTS, ANALGESICS, ANTIPYRETICS MERCK FROSST CANADA, INC. (CA) 1997-02-18 — — US disclosed
WO-1996003377-A1 HETEROCYCLIC COMPOUNDS, USEFUL AS ALLOSTERIC EFFECTORS AT MUSCARINIC RECEPTORS SANKYO COMPANY, LIMITED (JP) 1996-02-08 — — WO disclosed
EP-0464604-B1 1-Indolylalkyl-4-(alkoxy-pyrimidinyl)piperazines BRISTOL MYERS SQUIBB CO (US) 1995-03-29 — — EP disclosed
EP-0464604-A2 1-Indolylalkyl-4-(alkoxy-pyrimidinyl)piperazines Bristol-Myers Squibb Company (US) 1992-01-08 — — EP disclosed
US-5077293-A Antidepressants BRISTOL-MYERS SQUIBB CO. (US) 1991-12-31 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250152518-A1 PEG LIPIDS AND USES THEREOF LIPA, LIPG, LIPC PLA2G4A 581/4885POLB 3396/4885HTR6 2780/4885
US-11905525-B2 Reduction of elimination of immune responses to non-intravenous, e.g., subcutaneously administered therapeutic proteins CD47, FCGR3B, MSR1 PLA2G4A 144/4885POLB 711/4885HTR6 4756/4885
US-20260034071-A1 HIGH-PURITY PEG LIPIDS AND USES THEREOF LNPEP, AUP1, PLTP PLA2G4A 1426/4885POLB 1279/4885HTR6 3037/4885
US-12151029-B2 PEG lipids and uses thereof LIPA, LIPG, LNPEP PLA2G4A 638/4885POLB 3410/4885HTR6 2756/4885
US-12383508-B2 High-purity peg lipids and uses thereof LIPA, HDLBP, PLTP PLA2G4A 436/4885POLB 3744/4885HTR6 4026/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.